Go to the list of all blogs
Scott Bell's Avatar
published in Blogs
Nov 17, 2026
TickeronGET DAILY SIGNALS
IHE vs XLV: Pharma Concentration or Broad Health Care Coverage?

IHE vs XLV: Pharma Concentration or Broad Health Care Coverage?

Key Takeaways

  • IHE is a concentrated, single-industry play on U.S. pharmaceuticals, while XLV spans the entire health care sector, including medical devices, insurers, and life sciences tools.
  • XLV is meaningfully cheaper at a 0.08% expense ratio versus 0.37% for IHE, a durable structural cost advantage.
  • IHE carries elevated concentration risk, with its two largest holdings representing roughly half of the portfolio.
  • XLV offers broader diversification across roughly 60 to 64 holdings and multiple health care sub-industries, reducing single-stock and single-segment risk.
  • Both funds are passively managed and market-cap weighted, but their differing sector exposure drives very different risk and return profiles.
  • Tickeron AI Verdict: XLV is the favored ticker, reflecting superior cost efficiency, diversification, and more balanced sector positioning.

Why Health Care ETFs Deserve a Closer Look

Health care remains one of the most durable and structurally supported segments of the U.S. equity market, driven by demographic aging, therapeutic innovation, and relatively defensive demand. Investors seeking exposure often confront a choice between a narrow, high-conviction pharmaceutical vehicle and a broad sector fund. IHE and XLV embody that trade-off. They are not direct competitors in strategy but represent alternative routes to similar investor goals: capturing health care growth while managing risk. This ETF comparison examines how their structural differences, cost profiles, and relative positioning shape outcomes across recent market cycles. I also checked this using Tickeron’s AI Screener to see how the two line up on key metrics.

A Closer Look at IHE

IHE is a passively managed exchange-traded fund that seeks to track the Dow Jones U.S. Select Pharmaceuticals Index, a capitalization-weighted benchmark of U.S. pharmaceutical companies. The fund holds roughly 57 positions, a relatively concentrated lineup for a sector product. Its top holdings are dominated by LLY (Eli Lilly) and JNJ (Johnson & Johnson), which together account for close to 50% of assets, followed by smaller weights in VTRS (Viatris), RPRX (Royalty Pharma), ZTS (Zoetis), PFE (Pfizer), MRK (Merck), BMY (Bristol-Myers Squibb), JAZZ (Jazz Pharmaceuticals), and ELAN (Elanco).

Because the fund focuses exclusively on pharmaceuticals, its exposure is essentially 100% concentrated in one industry. This is a high-conviction, thematic approach: investors get pure drug-manufacturer exposure but absorb outsized single-stock risk and sensitivity to drug-pricing headlines, patent cliffs, and clinical-trial outcomes. The expense ratio is 0.37%, higher than broad sector peers.

A Closer Look at XLV

XLV is a passively managed ETF that seeks to track the Health Care Select Sector Index, which draws health care companies from the S&P 500. It holds roughly 60 to 64 large-cap names spanning pharmaceuticals, biotechnology, health care equipment and supplies, health care providers and services, and life sciences tools. Top holdings include LLY (Eli Lilly), JNJ (Johnson & Johnson), ABBV (AbbVie), MRK (Merck), UNH (UnitedHealth Group), TMO (Thermo Fisher Scientific), AMGN (Amgen), GILD (Gilead Sciences), ABT (Abbott Laboratories), and PFE (Pfizer). From what I see in the data, the broader mix helps moderate swings.

This diversified sector allocation is the fund's defining feature. By spreading exposure across manufacturers, equipment makers, insurers, and diagnostics firms, XLV dilutes any single company's influence and smooths the impact of one sub-industry's downturn. Its expense ratio of 0.08% is among the lowest in the category, and its substantial scale and trading volume support tight spreads and strong liquidity for institutional and retail investors alike.

The Current Health Care Backdrop

The broader health care environment has been shaped by several overlapping forces. GLP-1 weight-loss drugs have powered significant growth for large pharmaceutical leaders, lifting the biggest holdings in both funds. At the same time, policy debate over drug pricing, Medicare reimbursement, and pharmacy benefit managers has created recurring headline risk, particularly for pure-play pharmaceutical and insurance exposures. Elevated-for-longer interest-rate expectations have weighed on higher-multiple biotechnology and growth names, while defensive cash flows have attracted capital seeking stability in uncertain macro conditions. Capital flows in recent market cycles have favored diversified health care vehicles over narrow industry funds, reflecting a preference for balanced risk in a volatile policy landscape.

Recent Performance and Positioning

In recent weeks and months, both funds have benefited from strength in their shared top holdings, especially LLY and JNJ. However, relative performance has diverged along structural lines. IHE has shown greater sensitivity to pharmaceutical-specific catalysts, producing more pronounced swings when drug-pricing rhetoric or obesity-drug news dominates headlines. Its concentration in two mega-cap names means its fund performance often tracks the earnings cycles of a narrow set of companies.

XLV, by contrast, has delivered steadier relative positioning, as strength in pharmaceuticals is partially offset by more muted performance in managed care or equipment names, and vice versa. Its lower beta and broader industry mix have made it less volatile across recent market cycles, a key consideration for investors prioritizing consistency over maximum upside capture.

Exploring ETF Opportunities with AI

I often turn to Tickeron’s AI Screener when comparing sector ETFs like these. It lets me quickly filter by expense ratio, holdings concentration, and sub-industry exposure to see how the risk profiles stack up. The tool has helped refine my own workflow for spotting balanced options without manual number crunching.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: IHE, XLV

Contributor

Scott Bell's AvatarScott Bell|Expert

I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking


IHE in upward trend: 10-day moving average crossed above 50-day moving average on October 28, 2026

The 10-day moving average for IHE crossed bullishly above the 50-day moving average on October 28, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 15, 2026. You may want to consider a long position or call options on IHE as a result. In 70 of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.

The Moving Average Convergence Divergence (MACD) for IHE just turned positive on October 15, 2026. Looking at past instances where IHE's MACD turned positive, the stock continued to rise in 41 of 51 cases over the following month. The odds of a continued upward trend are 80%.

IHE moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +1.29% 3-day Advance, the price is estimated to grow further. Considering data from situations where IHE advanced for three days, in 286 of 343 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.

The Aroon Indicator entered an Uptrend today. In 246 of 288 cases where IHE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 85%.

Bearish Trend Analysis

The 10-day RSI Indicator for IHE moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 36 similar instances where the indicator moved out of overbought territory. In 25 of the 36 cases, the stock moved lower in the following days. This puts the odds of a move lower at 69%.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IHE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 78%.

IHE broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co (NYSE:MRK), Pfizer (NYSE:PFE), Bristol-Myers Squibb Co (NYSE:BMY), ZOETIS (NYSE:ZTS), Elanco Animal Health (NYSE:ELAN).

Industry description

The investment seeks to track the investment results of the Dow Jones U.S. Select Pharmaceuticals Index. The underlying index includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines. The fund generally will invest at least 80% of its assets in the component securities of its underlying index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. The fund is non-diversified.

Market Cap

The average market capitalization across the iShares U.S. Pharmaceuticals ETF (IHE) ETF is 63.11B. The market cap for tickers in the group ranges from 31.04M to 1.21T. LLY holds the highest valuation in this group at 1.21T. The lowest valued company is EYPT at 31.04M.

High and low price notable news

The average weekly price growth across all stocks in the iShares U.S. Pharmaceuticals ETF (IHE) ETF was -0%. For the same ETF, the average monthly price growth was 8%, and the average quarterly price growth was 23%. LQDA experienced the highest price growth at 18%, while ALMS experienced the biggest fall at -22%.

Volume

The average weekly volume growth across all stocks in the iShares U.S. Pharmaceuticals ETF (IHE) ETF was -17%. For the same stocks of the ETF, the average monthly volume growth was -5% and the average quarterly volume growth was -21%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 54
P/E Growth Rating: 51
Price Growth Rating: 46
SMR Rating: 74
Profit Risk Rating: 68
Seasonality Score: 13 (-100 ... +100)
1-on-1 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
Interact to see
Advertisement
NVIDIA shares declined roughly 26% over the 30 days ending mid-November, falling from a close near $221 to $162.85. The drop left the stock about 30% below its October 6 record intraday high of $243.37 and at a 52-week low.
Different growth engines: MRVL is riding accelerating AI data-center demand for custom chips and networking, while QCOM remains heavily tied to a soft smartphone market. Momentum contrast: Marvell's data-center revenue guidance has strengthened, whereas Qualcomm's near-term outlook has been pressured by memory-supply constraints and shrinking handset volumes.
TMC fell from Monday's $2.11 close to $1.96 by 10:10 a.m. ET, a -7.11% decline that occurred entirely in the regular session after an early premarket gain faded. No verified news or fundamental catalyst found for the drop; the move is likely technical, extending the post-Q3 unwind that followed NOAA pushing its certification decision to mid-December, with the stock averaging a 4.0% daily swing and logging 11 sessions of 7%-or-larger moves in the last 60.
Micron shares fell -6.28% to $729.40 from Friday's $778.31 close, gapping lower in premarket trading and holding those losses into Monday's regular session. The decline was sector-driven, not company-specific: memory peers SanDisk, SK hynix and Western Digital slid in tandem as last week's Nvidia CEO departure revived doubts over AI data-center spending, financing and memory demand durability.
SKHY fell -6.87% to $122.74 by 10:04 a.m. ET, down $9.05 from Friday's close of $131.79, extending a premarket decline into the regular session. The drop was driven by a sector-wide AI chip selloff ahead of Nvidia's quarterly results on Tuesday, where CEO Jensen Huang's resignation has raised doubts about the durability of data-center spending that underpins high-bandwidth memory demand.